Lugano ReversedA biotech startup that earns the geni and advanced molecular simulations, its first funds to reduce the time and cost of drugs in the pharmaceutical sector have closed € 2.85 million.
This startup won the first prize for the Boldbrose Startup Challenge, with the Agraha Foundation in collaboration with the University of Italian Switzerland (USI), with the help of the innovative concepts organized by the Agar Foundation and with the help of the Department of Finance and Economics and the Department of Finance and Economics and Bansato. Inviritulabs is supported by the USI Startup Center in its incubation programs.
“The consolidation of artificial intelligence, chemistry and molecular biophagics is mainly changing the method of developing our drugs” Gianvito GrasoThe founder and CEO of Inviriolabs, and the IDSIA researcher and lecturer-Dali Moli Institute for Artificial Intelligence (USI-Supreme). “Our system is not limited to the existing data analysis, but the best for functionality and protection identifies billions of new molecules and tests. Specifically, we want to accelerate the development of rare diseases, a region that still lacks adequate solutionsThe “
Established in 2024 by Gianvito Graso, Stefano Mascot and Sartak Yeltekin, Inviritulabs is inventing drugs by integrating AI with molecular simulations. Their platform combines advanced machine learning techniques, including multimodal learning, active learning and generator chemistry, to explore chemical space efficiently.
By utilizing this combination, they aim to quickly identify and adapt the pledged drug candidates by accelerating the path to life-changing therapy.
The Inviritulabs team combines experts in the pharmaceutical industry for more than 50 years of experience, as well as companies such as Fiazer, Novo Nordisk, Boxer and Helcin Healthcare, as well as machine learning specialists in machine learning.
In the next 18 months, the startup plans to expand with the goal of strengthening the team, starting strategic cooperation and expanding the capacity of the platform.
The next generation of virtual lab at the center of the innovation of Ingiriolab; The platform they owned was used to identify and adapt the drugs accurately. This method is allowed to double the success rate compared to the current research system, reduce both expenses, $ 2.5 billion per drug and during development, currently 12 years – according to statistics provided by Inviritulabs.
“The company is located in the cros of artificial intelligence, pharmaceutical innovation and biotechnology“Added Sartak YeltecinFounder and COO of Inviriolabs. “This ambitious project depends on the three basic pillars: attraction to investors, the ability to appoint and hold global talent in AI and the possibility of generating concrete social impact.“
The first major achievement of the platform was the main protein in controlling basic processes such as developing a protocol for drugs, metabolism, cell growth and inflammatory reactions. These receptors are involved in more than 100 diseases, including metabolic disorders and some cancers.
Invirituolabs is already applying this protocol to a receptor associated with high-occurrence metabolic diseases to accelerate the discovery of new treatment.
[publish_date
